ClinicalTrials.gg
RecruitingNCT04642430COBRRA-AFUpdated Oct 1, 2026

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

A Phase 4 interventional study of Apixaban and Rivaroxaban in Atrial Fibrillation, sponsored by Ottawa Hospital Research Institute. Recruiting at 8 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Ottawa Hospital Research Institute · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.
Updated Oct 1, 2026Site recruiting status changedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,018
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing apixaban in Atrial Fibrillation — 10 open to participants now, 11 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.

Planned enrollment
7th of 30
3,018 · median 498
Started
2021
the only one that year
Phase 4
13 of 30
5 open now
Primary completion
2027-12
later than 3 of 10 live
Registered
24th of 30
by date

Among the 30 studies testing apixaban in Atrial Fibrillation, this one is the 7th largest by planned enrollment, is the only one that started in 2021, is one of 13 in phase 4, reaches primary completion later than 3 of the 10 other live ones, and was the 24th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

10 of the 30 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing apixaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

Atrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Having a stroke can affect a patient's ability to speak, eat, walk, work, care for themselves, and interact with others. Not only can it ruin one's life, but it can also be fatal. A stroke occurs when blood flow to the brain is blocked by a clot, depriving brain cells of oxygen. In people with atrial fibrillation, blood flow is sluggish in the top chambers of the heart, and blood clots can form there. When a piece of a clot breaks off, it can travel to the brain and cause a stroke. That's where blood thinners come in. Blood thinners, or anticoagulants, decrease the chances of blood clots forming in the heart, reducing the risk of stroke. Studies show that blood thinners are highly effective at reducing the risk of stroke by up to 95%.

The conventional blood thinner is warfarin, taken by mouth. Warfarin requires regular blood tests to make sure a patient getting the correct dose. The patient also may have to avoid certain foods since the medication can interact with them. Newer blood thinners, known as direct-oral anticoagulants (DOACs) are available, which do not require regular blood tests and do not interact with foods. Two of the new blood thinners are called rivaroxaban and apixaban. Like warfarin, they can be taken by mouth, and studies have shown them to be as effective as warfarin.

Both rivaroxaban and apixaban have been approved for stroke prevention in AF by Health Canada. However, there have been no direct head-to-head comparisons of these two anticoagulants, meaning comparative safety data is not available. Increasing use of DOACs for stroke prevention in AF and patient values around bleeding highlight the need for a comparison trial to ensure patients receive the anticoagulant with the greatest balance of benefit to potential harm.

The trial is to assess bleeding rates and superiority of using apixaban versus rivaroxaban in patients with non-valvular atrial fibrillation.

Read the detailed description

Atrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Oral anticoagulants such as Vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) are highly effective at reducing the risk of stroke by up to 95%. Randomized controlled trials (RCTs) have compared apixaban and rivaroxaban (both DOACs) to VKAs for stroke prevention in AF, and are approved for this use by Health Canada. However, there have been no direct head-to-head comparisons of these two anticoagulants, meaning comparative safety data is not available. Increasing use of DOACs for stroke prevention in AF, patient values around bleeding, and litigation highlight the need for a comparison trial to ensure patients receive the anticoagulant with the greatest balance of benefit to potential harm.

The objective of this RCT is to compare the safety of the first 12 months of apixaban twice daily to rivaroxaban once daily in patients with non-valvular AF (NVAF). Patients will be monitored for the primary outcome of clinically relevant bleeding (CRB; a composite of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB) events during follow-up. This trial will directly inform clinical practice and the choice of first-line therapy.

03

Conditions studied

  • Atrial Fibrillation

Keywords

  • Stroke Prevention
  • Bleed
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Confirmed new diagnosis of AF on with an indication to start anticoagulation according to Canadian Cardiovascular Society guidelines

Exclusion criteria

Exclusion Criteria:

  • =\<15 ml/min calculated using the Cockcroft-Gault formula
  • Any for anticoagulation with apixaban or rivaroxaban as determined by the treating physician such as, but not limited to:

    • active bleeding
    • history of mechanical valve
    • other indication for anticoagulation (e.g. mechanical valves, venous thrombosis)
    • dual antiplatelet agent use
    • known liver disease with coagulopathy
    • use of contraindicated medications (strong inducers/inhibitors of CYP 3A4/5, P-glycoprotein)
    • pregnancy or breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
3,018 participants (estimated)

Study arms

  • Active comparator
    Apixaban group

    5 mg PO, twice daily for 12 months of treatment. A dose reduction\* to 2.5 mg twice daily will apply if patients meet 2 of 3 following criteria: age \> 80 years; weight \< 60 kg; creatinine \>133 micromol/L. \*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually

    Drug: Apixaban

  • Active comparator
    Rivaroxaban Group

    20 mg PO, once daily for 12 months of treatment. A dose reduction\* to 15 mg daily will apply to patients with creatinine clearance \<50 ml/min. \*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually

    Drug: Rivaroxaban

Interventions

  • Refer to Apixaban group

    Also known as: Eliquis

  • Refer to Rivaroxaban group

    Also known as: Xarelto

06

What researchers measure

Primary outcomes

  1. The rate of adjudicated clinically relevant bleeding (CRB) events

    CRB events are defined as the composite of major bleeding (MB) events and clinically relevant non-major bleeding (CRNMB) events

    Time frame: For the duration of the study: 12 months

Secondary outcomes

  1. Adjudicated Major Bleeding events

    Major Bleeding includes clinically overt bleeding and is associated with: * Fatal bleeding, and/or * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or * A fall in hemoglobin of ≥20 g/L, or * Leading to transfusion of ≥2 units of whole blood or red cells.

    Time frame: For the duration of the study: 12 months

  2. Adjudicated Clinically Relevant Non-Major Bleeding events

    Clinically relevant non-major bleeding will be defined as: • Any sign or symptom of hemorrhage (e.g., more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for the ISTH definition of major bleeding but does meet at least one of the following criteria: * Requiring medical intervention by a healthcare professional * Leading to hospitalization or increased level of care * Prompting a face to face (i.e., not just a telephone or electronic communication) evaluation

    Time frame: For the duration of the study: 12 months

  3. Adjudicated stroke/TIA events

    Stroke is defined as non-traumatic focal neurologic deficit lasting ≥ 24 hours and confirmed on cerebral imaging (computed tomography or magnetic resonance imaging). Transient ischemic attack (TIA) is defined as a temporary loss of blood flow to a part of the brain with focal neurologic deficit lasting \< 24 hours without imaging evidence of acute infarction. Strokes are to be classified as ischemic, hemorrhagic stroke, or uncertain. Hemorrhagic strokes are considered and will be reported as both bleeding events as well as stroke endpoints. The location of the bleeding can be determined from the diagnostic imaging reports.

    Time frame: For the duration of the study: 12 months

  4. All-cause mortality

    Using a binary outcome of an event or no event (Individual rates of death, all causes).

    Time frame: For the duration of the study: 12 months

  5. Medication adherence

    Reported as the number of patients self-reporting "all assigned medications were taken" "missing at least one dose of study medication", or "not able to take all of the study medications" out of the total number of medication compliance assessments done respectively

    Time frame: For the duration of the study: 12 months

  6. Incremental cost-effectiveness ratio

    We will model the prognosis of a cohort of patients receiving rivaroxaban versus apixaban. The results will be presented as incremental cost per QALY gained, incremental costs per one clinically relevant bleeding cases prevented, and incremental cost per one life year saved.

    Time frame: For the duration of the study: 12 months

07

Study locations

6 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2027, 77 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 77 months is above that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2020
First posted
Nov 24, 2020
StartActual
Jul 6, 2021
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Victoria Cardiac Arrhythmia Trials is now Withdrawn
Oct 1, 2026
Contact
Study contact changed: l•••@toh.ca · •••8899→l•••@toh.ca · •••8899; •••8899→none listed. See the current contact
Oct 1, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • Victoria Cardiac Arrhythmia Trials · Victoria, CanadaContact removed m•••@catrials.orgContact removed m•••@catrials.orgContact removed (no phone or email listed)
  • QEII Health Science Centre · Halifax, CanadaContact none listed→k•••@nshealth.caContact added (no phone or email listed)
  • Kingston General Hospital · Kingston, CanadaContact none listed→h•••@kingstonhsc.caContact added t•••@kingstonhsc.caContact added (no phone or email listed)
  • The Ottawa Hospital - General Campus · Ottawa, CanadaContact l•••@toh.ca→d•••@ohri.ca · •••8899Contact •••8899→none listedContact added (no phone or email listed)
  • University Ottawa Heart Institute · Ottawa, CanadaContact none listed→h•••@ottawaheart.ca · •••7000Contact added c•••@ottawaheart.caContact added (no phone or email listed)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Victoria Cardiac Arrhythmia Trials is now Withdrawn
    Contact Study contact changed: l•••@toh.ca · •••8899→l•••@toh.ca · •••8899; •••8899→none listed. See the current contact
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Victoria Cardiac Arrhythmia Trials · Victoria, CanadaContact removed m•••@catrials.orgContact removed m•••@catrials.orgContact removed (no phone or email listed)
    • QEII Health Science Centre · Halifax, CanadaContact none listed→k•••@nshealth.caContact added (no phone or email listed)
    • Kingston General Hospital · Kingston, CanadaContact none listed→h•••@kingstonhsc.caContact added t•••@kingstonhsc.caContact added (no phone or email listed)
    • The Ottawa Hospital - General Campus · Ottawa, CanadaContact l•••@toh.ca→d•••@ohri.ca · •••8899Contact •••8899→none listedContact added (no phone or email listed)
    • University Ottawa Heart Institute · Ottawa, CanadaContact none listed→h•••@ottawaheart.ca · •••7000Contact added c•••@ottawaheart.caContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04642430
Collaborators
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Nov 24, 2020
Start date
Jul 6, 2021
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Lana Castellucci, MD
Contact
lcastellucci@toh.ca
613-737-8899 ext. 75481
Erin Thomas
Contact
erithomas@toh.ca
Lana Castellucci, MD, FRCPC
principal investigator · Ottawa Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apixaban · Rivaroxaban

Start the discussion